Skip to main content
TipRanks
Go Ultimate75% OFF

Universal Health (UHS) AI Stock Analysis

602 Followers
UHS

Universal Health

(NYSE:UHS)

Select Model
Rating:74Outperform
Price Target:$220.00â–²(18.24% Upside)
Action:reiterated
Date:11/05/26

UHS scores well on valuation (low P/E) and technical trend strength (price above key moving averages with positive MACD). Financial performance is solid but held back by weaker cash conversion and a modest recent rise in leverage. The latest earnings call tempers the score due to lower-end 2026 positioning and meaningful 2027 Medicaid and exchange-related headwinds despite improving underlying operating trends.

Positive Factors
Steady revenue growth and profitabilitySteady revenue growth combined with healthy operating, EBITDA, and net margins indicates a durable earnings base. This profitability gives UHS capacity to fund expansion, absorb moderate cost pressure, and sustain investment across acute care and behavioral health services over the coming quarters.
Negative Factors
Material 2027 Medicaid and exchange reimbursement headwindsThe expected loss of supplemental Medicaid payments creates a meaningful structural pressure on future earnings, while exchange enrollment declines add further reimbursement strain. These effects may persist beyond one quarter and could offset operating improvements across affected states and facilities.

Universal Health Key Performance Indicators (KPIs)

Segment Net Revenue BreakdownBreaks down net revenue by segment to show where money is earned and how the revenue mix is shifting; useful for identifying growth drivers, pricing power, and concentration risks if revenue depends on a few segments.

$0.00$1.00B$2.00B$3.00B$4.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Acute care remains UHS’s revenue engine, but behavioral health is growing faster and materially narrowing the gap—shifting the company toward a more diversified, less cyclical revenue mix. The acceleration since 2024 suggests stronger volume/pricing or strategic expansion (organic openings or deals); investor focus should be on management’s cadence for new bed capacity, acquisitions, payer mix and staffing constraints, which will determine whether this mix shift drives durable margin improvement or simply revenue growth without proportional earnings leverage.

Data provided by:The Fly

Universal Health (UHS) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%UHS-19.42%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.68B
Dividend Yield
0.43%
Average Volume (3M)
701.53K
Price to Earnings (P/E)
7.7
Beta (1Y)
0.35
Revenue Growth
8.00%
EPS Growth
13.14%
Country
US
Employees
102,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Universal Health Business Overview & Revenue Model

Company Description

Universal Health Services, Inc. (UHS), operating through its various divisions, is a healthcare entity that both owns and manages a network of acute care hospitals, along with outpatient and specialized behavioral health treatment centers. Its busine...

How the Company Makes Money

UHS generates revenue primarily by providing healthcare services at its owned and operated facilities and being reimbursed by third-party payers, patients, and government programs. (1) Acute Care segment: UHS earns money from patient service revenue...

Universal Health Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:4.93%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentNeutral

The call reflected a mixed but cautiously constructive outlook. UHS reported solid acute care admissions, emergency department visits, behavioral health volumes, cash flow, labor trends, and strategic progress in outpatient access and Talkspace integration. However, these positives were offset by lower adjusted EPS and EBITDA, slower de novo hospital ramps, a decline in surgical volumes, Laurel Ridge losses, exchange-related pressure, and substantial expected Medicaid supplemental payment headwinds. Management reiterated guidance but expects 2026 results toward the lower end of the ranges, making the overall tone balanced.

Positive Updates

Sequential Operating Improvement
Underlying third-quarter performance reflected sequential improvement in several areas: acute care demand remained strong, behavioral health volumes increased relative to recent quarters, labor trends continued to moderate, and expense management remained disciplined.

Negative Updates

Adjusted EPS and EBITDA Decline
Third-quarter adjusted EPS was $5.22, down 8% year over year. Adjusted EBITDA less NCI was $625 million, compared with $671 million in the third quarter of 2025.

Company Guidance

UHS reiterated its financial and operating forecast ranges issued with its second quarter results in July and currently expects results to be towards the lower end of these ranges; it expects Cedar Hill Regional Medical Center to reach operational break even in the first half of 2027, Laurel Ridge Treatment Center recertification during 2027, and facilities incurring operating losses during 2026 of $80 million-$100 million to recover at least a meaningful portion of those losses in 2027. The company estimates a 2027 Medicaid supplemental payments headwind of approximately $175 million-$200 million, including approximately $10 million during the fourth quarter 2027 from the initial provider tax portion of the OB3 funding cuts, while annualizing the second half 2026 exchange run rate would create a $15 million headwind in 2027; it has no estimate for Medicaid work requirements. UHS expects capital expenditures to be slightly below $1 billion for the full-year of 2026 and to moderate towards $800 million beyond 2026, with its acute care growth algorithm at 1.5%-2.5% adjusted admission growth and 2%-3% pricing growth and its behavioral health algorithm at 1%-2% adjusted patient day growth and 2%-3% pricing; Talkspace synergies are expected over the first 12-24 months of ownership, with the transaction expected to be slightly accretive in the first 12 months.

Universal Health Financial Statement Overview

Summary

Fundamentals are solid: steady revenue growth and durable profitability (TTM operating margin ~11.5%, EBITDA margin ~15.1%, net margin ~8%). Offsets include slightly softer margins vs. 2025, a modest uptick in leverage (debt-to-equity ~0.81 TTM), and weaker cash conversion (operating cash flow below net income across periods despite improved free cash flow).

Income Statement

78Positive

Balance Sheet

72Positive

Cash Flow

66Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue18.35B17.36B15.83B14.28B13.40B12.64B
Gross Profit12.80B15.71B14.24B12.75B11.93B11.21B
EBITDA2.78B2.74B2.27B1.72B1.58B1.91B
Net Income1.46B1.49B1.14B717.79M675.61M991.59M
Balance Sheet
Total Assets17.19B15.96B14.47B13.97B13.49B13.09B
Cash, Cash Equivalents and Short-Term Investments168.75M137.80M125.98M119.44M102.82M115.30M
Total Debt6.18B5.51B4.96B5.37B5.27B4.56B
Total Liabilities9.52B8.55B7.71B7.77B7.52B6.90B
Stockholders Equity7.60B7.28B6.67B6.15B5.92B6.09B
Cash Flow
Free Cash Flow1.12B849.25M1.12B524.74M262.02M28.04M
Operating Cash Flow2.06B1.86B2.07B1.27B996.02M883.70M
Investing Cash Flow-1.87B-1.07B-911.11M-763.27M-647.30M-914.47M
Financing Cash Flow-101.79M-749.73M-1.14B-493.94M-318.40M-1.07B

Universal Health Technical Analysis

Technical Analysis SentimentPositive
Last Price186.07

Price Trends

50DMA182.15Positive
100DMA172.90Positive
200DMA176.12Positive

Market Momentum

MACD4.28Negative
RSI54.74Neutral
STOCH44.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UHS, the sentiment is Positive. The current price of 186.07 is below the 20-day moving average (MA) of 188.06, above the 50-day MA of 182.15, and above the 200-day MA of 176.12, indicating a bullish trend. The MACD of 4.28 indicates Negative momentum. The RSI at 54.74 is Neutral, neither overbought nor oversold. The STOCH value of 44.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UHS.

Universal Health Risk Analysis

Universal Health disclosed 32 risk factors in its most recent earnings report. Universal Health reported the most risks in the "Production" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

3 New Risks
1.The success of our acquisition of Talkspace, Inc. is subject to numerous risks and uncertainties.Q3, 2026
2.The success of our acquisition of Talkspace, Inc. is subject to numerous risks and uncertainties.Q2, 2026
3.The success of our acquisition of Talkspace, Inc. is subject to numerous risks and uncertainties.Q1, 2026

Universal Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

UHS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
THCTHC87Outperform$22.45B7.8260.60%―6.23%136.09%
UHSUHS74Outperform$10.73B7.7219.54%0.43%8.00%13.14%
EHCEHC70Outperform$13.53B20.8225.17%0.58%9.36%20.78%
HCAHCA64Neutral$99.51B15.74-100.45%0.64%5.82%16.59%
ACHCACHC53Neutral$3.53B-3.01-57.05%―4.47%-1156.09%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CYHCYH44Neutral$284.87M6.89-2.51%―-7.84%-88.93%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%UHSACHCCYHHCAEHCTHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
UHS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
UHSUniversal Health Services186.07-38.33-17.08%
ACHCAcadia Healthcare Company, Inc.37.5923.23161.77%
CYHCommunity Health Systems1.86-1.08-36.73%
HCAHca Healthcare476.353.310.70%
EHCEncompass Health134.9322.9720.52%
THCTenet Healthcare Corp.271.3484.6645.35%

Universal Health Corporate Events

Private Placements and Financing

Universal Health Completes $1.1 Billion Senior Notes Offering

Positive
Aug 21, 2026

On August 20, 2026, Universal Health Services, Inc. completed a public offering of $1.1 billion in senior secured notes, issuing $600 million of 5.500% notes due 2031 and $500 million of 6.000% notes due 2036, both guaranteed on a senior secured basi...

Business Operations and StrategyM&A TransactionsPrivate Placements and Financing

Universal Health completes Talkspace behavioral health acquisition

Positive
Aug 17, 2026

On August 17, 2026, Universal Health Services completed its acquisition of virtual behavioral health platform Talkspace, following a merger in which Talkspace became an indirect wholly owned subsidiary. UHS financed the cash purchase, including $5.25...

Business Operations and StrategyPrivate Placements and Financing

Universal Health Announces $1.1 Billion Senior Notes Offering

Neutral
Aug 13, 2026

On August 11, 2026, Universal Health Services, Inc. and certain subsidiaries entered into an underwriting agreement to issue $1.1 billion of senior secured notes, comprising $600 million of 5.500% notes due 2031 and $500 million of 6.000% notes due 2...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026